Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Nakamura

Showing results (541-550 of 709) with videos related to

Pageof 71
Sort By:
American Heart Journal|September 11, 2013
A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosisSeiji Habara, Masashi Iwabuchi, Naoto Inoue, et al.
Surgery|February 1, 2007
Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resectionYubo Yang, Hiroaki Nagano, Hideo Ota, et al.
International Journal of Clinical Oncology|April 20, 2007
Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomyTameyoshi Yamamoto, Hiroaki Nagano, Yasuharu Imai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cellsMotoi Kondo, Hiroaki Nagano, Hiroshi Wada, et al.
Oncotarget|July 26, 2018
Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2015
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trialKazuhiro Nishikawa, Kazumasa Fujitani, Hitoshi Inagaki, et al.
American Journal of Physiology. Cell Physiology|September 9, 2024
Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesisJunjie Ao, Na Qiang, Hiroaki Kanzaki, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 2, 2024
Antithrombotic therapy for stable coronary artery disease and atrial fibrillation in patients with and without revascularisation: the AFIRE trialTakashi Noda, Kotaro Nochioka, Koichi Kaikita, et al.
Oncology Reports|September 6, 2007
Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietinsHiroshi Wada, Hiroaki Nagano, Hirofumi Yamamoto, et al.
Plos One|January 27, 2022
Impact of acute decompensation on the prognosis of patients with hepatocellular carcinomaTakayuki Kondo, Keisuke Koroki, Hiroaki Kanzaki, et al.
Pageof 71

Showing results (541-550 of 709) with videos related to

Sort By:
Pageof 71
American Heart Journal|September 11, 2013
A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosisSeiji Habara, Masashi Iwabuchi, Naoto Inoue, et al.
Surgery|February 1, 2007
Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resectionYubo Yang, Hiroaki Nagano, Hideo Ota, et al.
International Journal of Clinical Oncology|April 20, 2007
Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomyTameyoshi Yamamoto, Hiroaki Nagano, Yasuharu Imai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cellsMotoi Kondo, Hiroaki Nagano, Hiroshi Wada, et al.
Oncotarget|July 26, 2018
Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2015
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trialKazuhiro Nishikawa, Kazumasa Fujitani, Hitoshi Inagaki, et al.
American Journal of Physiology. Cell Physiology|September 9, 2024
Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesisJunjie Ao, Na Qiang, Hiroaki Kanzaki, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 2, 2024
Antithrombotic therapy for stable coronary artery disease and atrial fibrillation in patients with and without revascularisation: the AFIRE trialTakashi Noda, Kotaro Nochioka, Koichi Kaikita, et al.
Oncology Reports|September 6, 2007
Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietinsHiroshi Wada, Hiroaki Nagano, Hirofumi Yamamoto, et al.
Plos One|January 27, 2022
Impact of acute decompensation on the prognosis of patients with hepatocellular carcinomaTakayuki Kondo, Keisuke Koroki, Hiroaki Kanzaki, et al.
Pageof 71